VirtualScopics Inc

VirtualScopics — Shareholder Meeting (June 2012)

42 slides from VirtualScopics's shareholder meeting presentation, Jun 12, 2012

  1. Slide 1: Annual Stockholders' Meeting June 12, 2012

    Annual Stockholders’ Meeting June 12, 2012

  2. Slide 2: Meeting Overview

    VirtualScopics All Rights Reserved 2 Meeting Overview Introductions and Opening Remarks • Robert Klimasewski, Chairman Proxy Summons Business Overview • Jeff Markin/Molly Henderson Question and Answer Proxy Tally and Results • Robert Klimasewski

  3. Slide 3: 2012 Proxy Summons

    VirtualScopics All Rights Reserved 3 2012 Proxy Summons Election of Board of Directors for 2012/2013 Ratify the appointment of Marcum LLP as independent financial statement auditors for the fiscal year ended December 31, 2012 To approve the issuance of common stock issuable upon full conversion of S

  4. Slide 4: Meeting Overview

    VirtualScopics All Rights Reserved 4 Meeting Overview Introductions and Opening Remarks • Robert Klimasewski, Chairman Proxy Summons Business Overview • Jeff Markin/Molly Henderson Question and Answer Proxy Tally and Results • Robert Klimasewski

  5. Slide 5: Forward-looking statements

    VirtualScopics All Rights Reserved 5 This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual

  6. Slide 6: Company Overview

    Company Overview Jeff Markin President and CEO Molly Henderson Chief Business & Financial Officer

  7. Slide 7: Business Meeting Agenda

    VirtualScopics All Rights Reserved 7 Business Meeting Agenda Business Overview - Clinical Trial Business - Personalized Medicine Business Financial Review - Historical summary - Industry comparisons and multiples - 2012 outlook Q & A

  8. Slide 8: Company Mission

    VirtualScopics All Rights Reserved 8 Our mission is to improve the lives of those impacted by disease and disability Company Mission

  9. Slide 9: Business Focus

    VirtualScopics All Rights Reserved 9 Business Focus Drug Development • 12 Years in the industry • Strong reputation doing business with 10 of the top 15 global pharmaceutical and Biotech companies • Significant Assets • Leading technology and Scientific position • Cash generating business model • St

  10. Slide 10: Business Focus

    VirtualScopics All Rights Reserved 10 Business Focus Drug Development • 12 Years in the industry • Strong reputation doing business with 10 of the top 15 global pharmaceutical and Biotech companies • Significant Assets • Leading technology and Scientific position • Cash generating business model • S

  11. Slide 11: Clinical Trials Focus

    VirtualScopics All Rights Reserved 11 Clinical Trials Focus VirtualScopics is a leading provider of quantitative imaging for clinical trials • Integrated solution delivered as a series of services that manage imaging trials from inception to submission to the regulatory authorities. • Highly automat

  12. Slide 12: Core Business Competencies

    VirtualScopics All Rights Reserved 12 Core Business Competencies Our ability to very accurately and precisely quantify change in biological structures and processes through the use of medical imaging and imaging science To manage and process very large quantities of information quickly and efficient

  13. Slide 13: Multi-Disciplinary Expertise

    VirtualScopics All Rights Reserved 13 Imaging Science Software VirtualScopics Imaged - Based Bio Markers Medicine Image Analysis Service » Expertise in imaging systems and imaging protocol design » Expertise in image acquisition quality control » Proprietary automated image quantification software »

  14. Slide 14: Clinical Trial Experience

    VirtualScopics All Rights Reserved 14 • Greater than 300 studies in total • Broad therapeutic area and study phase experience • Delivering both diversity and depth Clinical Trial Experience 52% 30% 5% 3% 9% Oncology Muskuloskeletal Device Cardiovascular Other 19% 43% 38% Pre-Clinical Early Phase Lat

  15. Slide 15: Corporate Initiatives – Clinical Trials

    VirtualScopics All Rights Reserved 15 Bookings Growth Customer Loyalty Productivity and Efficiency Employee Satisfaction Growth of the PPD Alliance Corporate Initiatives – Clinical Trials

  16. Slide 16: Bookings Growth

    VirtualScopics All Rights Reserved 16 • Experienced a slowdown in new study awards • Series of actions to assess the situation – Critical assessment of our strengths and weaknesses along with client interviews and an assessment of the morale and satisfaction of our employees – Broad set of discussio

  17. Slide 17: Direct PPD Q1 RFP Performance

    VirtualScopics All Rights Reserved 17 Direct PPD Q1 RFP Performance - Quantity Goal Actual Bookings Growth - RFP Objectives Represents a 50% increase in direct RFP’s and 100% increase in RFP’s through PPD! Working to raise win rate across both channels

  18. Slide 18: PPD Company Overview

    PPD Company Overview Development services since 1985 Revenue in excess of $1.4B and project backlog $3.4B Recognized by Forbes as one of America’s best big companies 11,000 + 84 professionals worldwide offices in 41 countries

  19. Slide 19: PPD Recent Awards & Recognition

    VirtualScopics All Rights Reserved 19 PPD Recent Awards & Recognition • Scrip Awards 2011 – PPD named Best Contract Research Organization and honored for Best Technological Development in Clinical Trials – Recognized for expertise and innovation in helping clients develop life - changing medical tre

  20. Slide 20: PPD – External Perspective on VS

    VirtualScopics All Rights Reserved 20 • Selection process sanctioned by PPD CEO and Executive Management Team • Assessed through visits and meetings all industry imaging players • Assessment criteria included – Experience in early phase through late phase – Capabilities across multiple therapeutic a

  21. Slide 21: Business Focus

    VirtualScopics All Rights Reserved 21 Business Focus Drug Development • 12 Years in the industry • Strong reputation doing business with 10 of the top 15 global pharmaceutical and Biotech companies • Significant Assets • Leading technology and Scientific position • Cash generating business model • S

  22. Slide 22: Business Focus

    VirtualScopics All Rights Reserved 22 Business Focus Drug Development • 12 Years in the industry • Strong reputation doing business with 10 of the top 15 global pharmaceutical and Biotech companies • Significant Assets • Leading technology and Scientific position • Cash generating business model • S

  23. Slide 23: Market Opportunity – Clinical

    VirtualScopics All Rights Reserved 23 • Emphasis on controlling the increasing cost of healthcare • Products and services that assist in patient stratification and rapid determination of efficacy or futility for expensive therapies are critical • Offer significant financial returns for organizations

  24. Slide 24: Benefits of Quantitative Imaging

    VirtualScopics All Rights Reserved 24 Precise measurements Repeatable results Enabling early diagnosis and drug mechanism of action confirmation Benefits of Quantitative Imaging Yet, the majority of assessments done today are still qualitative Significant opportunity to expand the imaging market by

  25. Slide 25: Economic Model

    VirtualScopics All Rights Reserved 25 Payers Payers see reduced cost through individual patients being on the right therapy Providers Providers receive more accurate information, allowing better treatment decisions. Patients Patients get on the right therapy sooner, enabling improved quality of life

  26. Slide 26: Quantitative Imaging Center - QIC

    VirtualScopics All Rights Reserved 26 Quantitative Imaging Center - QIC A centralized lab that receives medical images from global healthcare facilities and processes and delivers back quantitative assessments enabling improved patient outcomes at reduced cost. The center will be the first of its ki

  27. Slide 27: Key Elements of the QIC

    VirtualScopics All Rights Reserved 27 Industry Consortia and funding - via Merck Investment Branded Infrastructure Seamless Gateway From the Modality Integrated Path for Results Tailored Analysis Infrastructure Key Elements of the QIC

  28. Slide 28: Merck Investment Focus

    VirtualScopics All Rights Reserved 28 Merck Investment Focus

  29. Slide 29: Merck Value

    VirtualScopics All Rights Reserved 29 Merck Value

  30. Slide 30: Corporate Initiatives – Personalized Medicine

    VirtualScopics All Rights Reserved 30 Reimbursement Strategy For DCE - MRI Application Standalone QIC Platform Design and Site Selection for Prospective Trial for DCE - MRI Acceptance by the FDA for Blood Flow Measurement Device Initiation of Scientific Advisory Board Corporate Initiatives – Persona

  31. Slide 31: Personalized Medicine: Commercialization Process

    VirtualScopics All Rights Reserved 31 QIC Plaque Volume Blood Perfusion Tumor Volume/ Burden Personalized Medicine: Commercialization Process Opportunity/ Initiation Concept and Feasibility Design, Development, and Clinical Validation Production and Distribution Planning Launch QIC/Infrastructure On

  32. Slide 32: Financial Overview

    Financial Overview Molly Henderson Chief Business & Financial Officer, Sr. Vice President

  33. Slide 33: Revenues & Gross Profit – Yearly Trends

    VirtualScopics All Rights Reserved 33 Revenues & Gross Profit – Yearly Trends $- $1 $2 $3 $4 $5 $6 $7 $8 2006 2007 2008 2009 2010 2011 Millions Annual Gross Profit $1 $3 $5 $7 $9 $11 $13 $15 2006 2007 2008 2009 2010 2011 Millions Annual Revenues

  34. Slide 34: Revenue composition: 2007-2011

    VirtualScopics All Rights Reserved 34 Revenue composition: 2007 - 2011 - 2 4 6 8 10 12 14 16 2007 2008 2009 2010 2011 Millions Revenues by Therapeutic Area Other Oncology Musculoskeletal - 2 4 6 8 10 12 14 16 2007 2008 2009 2010 2011 Millions Revenues by Phase of Study Other R&D Phase III Phase II P

  35. Slide 35: Adjusted EBITDA – Yearly Trend

    VirtualScopics All Rights Reserved 35 Adjusted EBITDA* – Yearly Trend Adjusted EBITDA improved over $4MM, >300%, from 2006 - 2011 *Adjusted EBITDA = Earnings/Loss less Depreciation, Amortization, Interest, Stock Compensation Expense and Loss on Derivative Revenues increased $9MM over the same period

  36. Slide 36: Industry Marketcap/Valuation Data

    VirtualScopics All Rights Reserved 36 Industry Marketcap /Valuation Data Industry CRO Healthcare IT Personalized Medicine Average and Range of Revenue Multiples 1.6x 1.0x - 2.3x 5.2x 3.2x - 8.6x 7.4x 1.5x – 20x Average and Range of EBITDA Multiples 18x 17x – 22x 45x 37x – 52x Variable VirtualScopics

  37. Slide 37: Capitalization

    VirtualScopics All Rights Reserved 37 Capitalization: NASDAQ: VSCP Common shares outstanding: 29MM Convertible preferred securities: 6MM Warrants/Options: 6.7MM NASDAQ 52 week range: $0.80 - $1.89 Market cap:~ $30MM Stockholder concentration (as of April 5, 2012): (Beneficial Ownership Percentages)

  38. Slide 38: Company Mission

    VirtualScopics All Rights Reserved 38 Our mission is to improve the lives of those impacted by disease and disability Company Mission

  39. Slide 39: 2012 Initiatives

    VirtualScopics All Rights Reserved 39 2012 Initiatives 2012 Initiatives Meet Financial Goals Drive PPD Alliance Personalized Medicine Deliver Infrastructure and Technology Investments

  40. Slide 40: Thank You – Question and Answer

    VirtualScopics All Rights Reserved 40 Thank You Question and Answer

  41. Slide 41: 2012 Proxy Tabulation

    VirtualScopics All Rights Reserved 41 2012 Proxy Tabulation Election of Board of Directors for 2012/2013 Ratify the appointment of Marcum LLP as independent financial statement auditors for the fiscal year ended December 31, 2012 To approve the issuance of common stock issuable upon full conversion

  42. Slide 42: Thank You

    VirtualScopics All Rights Reserved 42 On behalf of the VirtualScopics’ Board of Directors and Employees Thank You

VirtualScopics — Shareholder Meeting (June 2012) on 6ix